A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT05083169 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05083169
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-14
- Primary completion
- 2025-09-15
- Enrollment
- 587
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.